Chemotherapy may result in the release of danger-associated molecular patterns (DAMPs), which can cause immunoparalysis (deactivation of the immune system). We investigated DAMPs following chemotherapy and their relationship with markers of immunoparalysis in leukemia patients. In 6 patients with acute myeloid leukemia or myelodysplastic syndrome and 12 healthy subjects, DAMPs, cytokines, and markers of immunoparalysis were determined before and during the first week after chemotherapy initiation. In the patients, plasma levels of nuclear DNA (a marker of general DAMP release) were profoundly increased before chemotherapy and further increased 4-6 h afterwards, while the specific DAMP mitochondrial DNA showed only a trend towards increase. Circulating cytokine levels did not change following chemotherapy. Leukocyte cytokine production capacity and HLA-DR expression were similar in patients and healthy controls until day 4 when leukocytes were found to be virtually absent. In conclusion, in the early phase following chemotherapy in leukemia patients, increased DAMP release does not induce immunoparalysis.

Keywords:
Danger-associated molecular patterns, Acute myeloid leukemia, Myelodysplastic syndrome, Leukemia, Immunoparalysis, HLA-DR
1.
Appelbaum FR: Haematopoietic cell transplantation as immunotherapy. Nature 2001;411:385-389.
2.
Sung L, Lange BJ, Gerbing RB, Alonzo TA, Feusner J: Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood 2007;110:3532-3539.
3.
Bodey GP, Buckley M, Sathe YS, Freireich EJ: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-340.
4.
Martin S, Baldock SC, Ghoneim AT, Child JA: Defective neutrophil function and microbicidal mechanisms in the myelodysplastic disorders. J Clin Pathol 1983;36:1120-1128.
5.
Estey E, Dohner H: Acute myeloid leukaemia. Lancet 2006;368:1894-1907.
6.
Srikrishna G, Freeze HH: Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia 2009;11:615-628.
7.
Matzinger P: The danger model: a renewed sense of self. Science 2002;296:301-305.
8.
Gentile LF, Moldawer LL: DAMPS, PAMPS, and the origins of SIRS in bacterial sepsis. Shock 2013;39:113-114.
9.
Leentjens J, Kox M, van der Hoeven JG, Netea MG, Pickkers P: Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change? Am J Respir Crit Care Med 2013;187:1287-1293.
10.
Hietbrink F, Koenderman L, Althuizen M, Pillay J, Kamp V, Leenen LP: Kinetics of the innate immune response after trauma: implications for the development of late onset sepsis. Shock 2013;40:21-27.
11.
Cajander S, Backman A, Tina E, Stralin K, Soderquist B, Kallman J: Preliminary results in quantitation of HLA-DRA by real-time PCR: a promising approach to identify immunosuppression in sepsis. Crit Care 2013;17:R223.
12.
Kox M, van Eijk LT, Zwaag J, van den Wildenberg J, Sweep FC, van der Hoeven JG, Pickkers P: Voluntary activation of the sympathetic nervous system and attenuation of the innate immune response in humans. Proc Natl Acad Sci USA 2014;111:7379-7384.
13.
Timmermans KK M, Gerretsen J, Peters E, Scheffer GJ, Verhoeven JG, Pickkers PP, Hoedemaekers CW: The involvement of danger-associated molecular patterns in the development of immunoparalysis in cardiac arrest patients. Crit Care Med 2015;43:2332-2338.
14.
McCarthy CG, Wenceslau CF, Goulopoulou S, Ogbi S, Baban B, Sullivan JC, Matsumoto T, Webb RC: Circulating mitochondrial DNA and toll-like receptor 9 are associated with vascular dysfunction in spontaneously hypertensive rats. Cardiovasc Res 2015;107:119-130.
15.
Kox M, Vrouwenvelder MQ, Pompe JC, van der Hoeven JG, Pickkers P, Hoedemaekers CW: The effects of brain injury on heart rate variability and the innate immune response in critically ill patients. J Neurotrauma 2012;29:747-755.
S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.